Xbrane beats Q1 consensus 5 times. Product launch strong
2023 and 2024 should be very regarding for Xbrane shareholders. xLucane is selling now in Europe, adding new countries every month. US market should open early next year. Revenues should grow exponentially.
Xbrane pre-announced its Q1 revenues last week as a part of capital raise. The company should be now fully funded, as the revenues starts to come in.
Next catalyst on Wednesday - Q1 Report
Full investment thesis here:
https://fitinvestmentideas.com/2022/11/28/xbrane-our-top-trade-idea-for-2023-24/
Xbrane pre-announced its Q1 revenues last week as a part of capital raise. The company should be now fully funded, as the revenues starts to come in.
Next catalyst on Wednesday - Q1 Report
Full investment thesis here:
https://fitinvestmentideas.com/2022/11/28/xbrane-our-top-trade-idea-for-2023-24/
NordicGuy
29.05.2023 kl 16:35
186
Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Wednesday, May 31th, 2023, at 11.00 a.m. CET. Xbrane will publish the company’s interim report January – March 2023, on Wednesday, May 31, 2023, at 8.00 a.m. CET.
Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – March 2023, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:
If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.
https://ir.financialhearings.com/xbrane-biopharma-q1-2023
Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – March 2023, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:
If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.
https://ir.financialhearings.com/xbrane-biopharma-q1-2023